Table 1 Subject characteristics
N | 210 |
|---|---|
Age ─ years | 70.6 ± 8.7 |
Male sex ─ no. (%) | 136 (64.7) |
Morphometric findings | Â |
 Body mass index ─ kg/m2 | 24.6 ± 4.1 |
 Waist circumference ─ cm | 88.6 ± 10.5 |
Blood pressure | Â |
 Systolic ─ mmHg | 133.5 ± 19.6 |
 Diastolic ─ mmHg | 73.9 ± 13.5 |
Laboratory measurements | Â |
 Serum creatinine ─ mg/dL | 0.9 ± 0.2 |
 Total cholesterol ─ mg/dL | 166.4 ± 31.7 |
 Triglycerides ─ mg/dL |  |
  Median (interquartile range) | 105 (77–143) |
 HDL cholesterol ─ mg/dL | 50.1 ± 13.7 |
 LDL cholesterol ─ mg/dL | 92.6 ± 23.0 |
 MDA-LDL ─ U/L | 99.0 ± 39.0 |
 Hemoglobin A1c ─ % | 6.9 ± 1.0 |
 Adiponectin ─ μg/dL |  |
  Median (interquartile range) | 13.3 (8.5 − 24.1) |
Current medications ─ no. (%) |  |
 Statins | 210 (100) |
 ACE-Is/ARBs | 152 (72.4) |
 β-Blockers | 132 (62.9) |
 Ca channel blockers | 85 (40.5) |
 Metformin | 84 (40.0) |
 Pioglitazone | 79 (37.6) |
 α-Glucosidase inhibitors | 70 (33.3) |
 Sulfonylurea | 61 (29.0) |
 Insulin therapy | 37 (17.6) |
 Phenylalanine derivatives | 14 (6.7) |
 DPP4 inhibitors | 15 (7.1) |
 EPA | 9 (4.3) |
 Ezetimibe | 1 (0.5) |